


Fig. 1

Control

Compound I

SLIGRL



BEST AVAILABLE COPY

Fig. 2


Control



Cpd.I



SLIGRL



BEST AVAILABLE COPY

Fig. 3

1000X 1000X 1000X 1000X

Control



STI




SLIGRL



BEST AVAILABLE COPY

Fig. 4A



BEST AVAILABLE COPY

Fig. 4B





Fig. 5A

Control



SLIGRL



STI



Cpdl



BEST AVAILABLE COPY


Figure 5B




BEST AVAILABLE COPY

Fig. 6A

Control



SLIGRL



Cpdl



BEST AVAILABLE COPY

Fig. 6B





Fig. 7A

Control

SLIGRL



BEST AVAILABLE COPY

Fig. 7B


Control



SLIGRL

BEST AVAILABLE COPY

Fig. 7C



Control

STI

BEST AVAILABLE COPY

Figure 8






Figure 9



BEST AVAILABLE COPY

Figure 10

Control




Anti ICAM-1 antibody



BEST AVAILABLE COPY

FIG 11



BEST AVAILABLE COPY